Marketed By
USV PVT LTD
Pack of
10 Capsule
Salt Composition
Atorvastatin (40mg) + Aspirin (75mg)
Storage
Keep in Cold Place
₹210
Tax: ₹25.20
1

Ecosprin AV 75/40 mg...
Delivering To: —
Indication
Dual action – prevents clots, reduces stroke risk
Indication
Prevent Blood Clots
Dosage And Administration
Ecosprin AV (75/40) mg Capsule is taken orally. Tablet is swallowed as it is with the help of water. It can be taken after or before food consumption (Prefer After Food). Avoid crushing, chewing, breaking or biting of tablet to maintain its efficacy. In general,Ecosprin AV (75/40) mg Capsule dosage in just one tablet at same time every day. For more personalized assistance and exact dosage, talk to your doctor about the same.
Mechanism Of Action
Ecosprin AV (75/40) mg Capsule functions in two ways: atorvastatin (40mg) competitively inhibits HMG-CoA reductase in the liver to reduce cholesterol biosynthesis, lowering LDL/triglycerides and stabilising plaques, while aspirin (75mg) irreversibly inhibits platelet COX-1 via acetylation to block thromboxane A2 synthesis and prevent aggregation/clot formation.
Faqs
Ecosprin AV (75/40) mg Capsule used to heart attacks, strokes, and cardiovascular events prescribed mainly for high-risk patients with dyslipidemia, atherosclerosis, post-heart attack/stroke prevention, angina, or peripheral artery disease.
Yes, Ecosprin AV (75/40) mg Capsule dosage is not fixed and thus vary. It all depends on the disease stage, extent, patient's health as well as side effects severity.
Yes, there are serious side effects of Ecosprin AV (75/40) mg Capsule , such as rhabdomyolysis (muscle breakdown), severe liver injury (jaundice, dark urine), gastrointestinal bleeding/perforation, severe allergic reactions (anaphylaxis), and myopathy etc.
Take Ecosprin AV (75/40) mg Capsule as soon as you remember it unless it is the time for the next dose. Do not double the dosage. Also inform your doctor about the missed dose.
Ecosprin AV (75/40) mg Capsule contains 75mg Aspirin and 40mg atorvastatin that lower down LDL cholesterol/triglycerides while inhibiting blood clot formation.
References
• Hebert, P. R., Pfeffer, M. A., & Hennekens, C. H. (2002). Use of statins and aspirin to reduce risks of cardiovascular disease. Journal of cardiovascular pharmacology and therapeutics, 7(2), 77-80.
• Tippabhotla, S. K., Betha, M. R., Gadiko, C., Battula, R., Nakkawar, M., Cheerla, R., ... & Vobalaboina, V. (2013). Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: A randomized, open-label, single-dose, two-way crossover study in healthy human subjects. Drug research, 63(05), 250-257.
• Farid, N. A., Small, D. S., Payne, C. D., Jakubowski, J. A., Brandt, J. T., Li, Y. G., ... & Winters, K. J. (2008). Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 28(12), 1483-1493.
• Hirsh, J., Dalen, J. E., Fuster, V., Harker, L. B., Patrono, C., & Roth, G. (1995). Aspirin and other platelet-active drugs: the relationship among dose, effectiveness, and side effects. Chest, 108(4), 247S-257S.
Ratings And Reviews
4.67/5
3 Ratings
5 Star
66.67%
4 Star
33.33%
3 Star
0.00%
2 Star
0.00%
1 Star
0.00%
10 months ago
8 months ago
View All Reviews
Related Products
MARKETER DETAILS
USV PVT LTD
DISCLAIMER
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.






